Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 1/2a study of intravesical KU002 in bladder pain syndrome/interstitial cystitis with Hunner lesions
NL-OMON52788Phase 2Completed
- Sponsor
- Kuste Biopharma
- Start
- Nov 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of brimapitide in Interstitial Cystitis-Bladder Pain Syndrome (IC/BPS), sponsored by Kuste Biopharma. Started Nov 2020; status: completed.
02
Drugs
brimapitide
03
Conditions
Interstitial Cystitis-Bladder Pain Syndrome (IC/BPS)
Beyond the preview
Go deeper on NL-OMON52788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52788.